pharma · Attention Deficit Disorder With Hyperactivity · Hidradenitis suppurativa (HS) · AVTX
Avalo Therapeutics
Avalo Therapeutics is a pharma organization headquartered in Chesterbrook, USA. It trades on NYSE under ticker AVTX. Primary therapeutic focus areas include Attention Deficit Disorder With Hyperactivity, Hidradenitis sup
Company details
- Status
- Public
- HQ
- 1500 Liberty Ridge Dr, Chesterbrook, Pennsylvania 19087, US
- Founded
- 2011
- Employees
- 48
- Programs
- 17
- Drugs
- 2
- Patents
- 10
CERC-006
Phase 1 · small molecule · Lymphatic Malformation
CERC-006 for Lymphatic Malformation is a Phase 1 program (small_molecule) at Avalo Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CERC-006-LM-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Avalo Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Lymphatic Malformation
- Status
- terminated
- Trials
- 1